Professional Documents
Culture Documents
Carmen Almansa,* Javier Bartrolı́, Jordi Belloc, Fernando L. Cavalcanti, Rosa Ferrando, Luis A. Gómez,
Isabel Ramis, Elena Carceller, Manuel Merlos, and Julián Garcı́a-Rafanell
Research Center, Grupo Uriach. Av. Camı́ Reial, 51-57, E-08184, Palau-Solità i Plegamans, Spain
vehicle control group (10 rats per group). Behavioral measure- (8) Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dubé,
ments (basically, differences in the paw withdrawal latency) D.; Ethier, D.; Falgueyret, J. P.; Friesen, R. W.; Gordon, R.;
were performed at 15, 30, 60, 120, and 240 min after Greig, G.; Guay, J.; Mancini, J.; Oellet, M.; Wong, E.; Xu, L.;
Boyce, S.; Visco, D.; Girard, Y.; Prasit, P.; Zamboni, R.; Rodger,
administration. Morphine (4 mg/kg iv), administered under I. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Can,
the same experimental conditions, was used as reference C. C. Etoricoxib (MK-0663): Preclinical Profile and Comparison
substance. with other Agents that Selectively Inhibit Cyclooxygenase-2. J.
Pharmacol. Exp. Ther. 2001, 296, 558-566.
Acknowledgment. We thank M. Carmen Torres, (9) Talley, J. J.; Bertershaw, S. R.; Brown, D. L.; Carter, J. S.;
Graneto, M. J.; Kellogg, M. S.; Koboldt, C. M.; Yuan, J.; Zhang,
Concepción González, Consol Ferreri, Guadalupe Mar- Y. Y.; Seibert, K. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]-
tı́nez, Nuria Recasens, Teresa Gamero, José Antonio sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent
Garcı́a, Ana Ester Sanahuja, Jordi Vilar, and Assumpta and Selective Inhibitor of COX-2 for Parenteral Administration.
J. Med. Chem. 2000, 43, 1661-1663.
Oliveras for their excellent technical assistance. (10) Almansa, C.; Alfon, J.; de Arriba, A. F.; Cavalcanti, F.; Escamilla,
I.; Gómez, L.; Miralles, A.; Bartroli, J.; Carceller, E.; Merlos, M.;
References Garcı́a-Rafanell, J. Synthesis and Structure-activity Relation-
ship of a new Series of COX-2 Selective Inhibitors: 1,5-
(1) Lewis, K. S.; Whipple, J. K.; Michael, K. A.; Quebbeman, E. J. Diarylimidazoles. J. Med. Chem. 2003, 46 (3), 3463-3475.
Effect of Analgesic Treatment on the Physiological Consequences (11) Larsen, J. D.; Bundgaard, H. Prodrug Forms for the Sulfonamide
of Acute Pain. Am. J. Hosp. Pharm. 1994, 51, 1539-1554.
Group. I Evaluation of N-Acyl Derivatives, N-Sulfonylamidines,
(2) Strom, B. L.; Berlin, J. A.; Kinman, J. L.; Spitz, P. W.; Hennessy,
N-Sulfonylsulfilimines and Sulfonylureas as Possible Prodrug
S.; Heldman, H.; Kimmel, S.; Carson, J. L. Parenteral Ketorolac
Derivatives. Int. J. Pharm. 1987, 37, 87-95.
and Risk of Gastrointestinal and Operative Site Bleeding: A
(12) Bundgaard, H.; Larsen, J. D. N-Sulfonyl Imidates as a Novel
Post-marketing Surveillance Study. J. Am. Med. Assoc. 1996,
275, 376-382. Prodrug Form for an Ester Function of a Sulfonamide Group.
(3) (a) Xie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; J. Med. Chem. 1988, 31, 2066-2069.
Simmons, D. L. Expression of a Mitogen-responsive Gene (13) Johnson, D. C.; Widlanski, T. S. Facile Synthesis of 5′-(N-acyl
Encoding Prostaglandin Synthase is Regulated by mRNA Splic- Sulfonamide) Derivatized Nucleosides. Tetrahedron Lett. 2001,
ing. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2692-2696. (b) 3677-3679.
Jujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; (14) MacKay, W. R.; Proctor, G. R. Removal of Toluene-p-Sulphonyl
Herschman, H. R. TIS10, a Phorbol Ester Tumor Promoter- Groups from Sulphonamides. Part 4. Synthesis of Phenylglyoxal
Inducible mRNA from Swiss 3T3 Cells, Encodes a Novel Pros- Imine Monomers. J. Chem. Soc., Perkin Trans. 1981, 31, 2435-
taglandin Synthase/Cyclooxygenase Homologue. J. Biol. Chem. 2442.
1991, 266, 12866-12872. (c) Vane, J. R. Towards a Better (15) Lukanov, L.; Venkov, A.; Mollov, N. The Application of Phase-
Aspirin. Nature 1994, 367, 215-16. (d) Masferrer, J. L.; Zweifel, Transfer Catalyzed Version of Atherton-Todd Reaction to Sul-
B. S.; Manning, P. T. Selective Inhibition of Inducible Cyclooxy- fonamides. Synth. Commun. 1986, 16, 767-773.
genase-2 in vivo is Antiinflammatory and Nonulcerogenic. Proc. (16) Rätz, R. Diethyl N-Arylsulfonylphosphoramidates. J. Org. Chem.
Natl. Acad. Sci. U.S.A. 1994, 91, 3228-3232. 1957, 22, 372-374.
(4) (a) Kalgutkar, A. S. Selective Cyclooxygenase-2 Inhibitors as (17) Goldstein, J. A. N-Alkyl (Aryl) Sulfonylphosphoramidate
Nonulcerogenic Antiinflammatory Agents. Exp. Opin. Ther. Monoesters. J. Org. Chem. 1977, 42, 2466-2469.
Patents 1999, 9, 831-849. (b) Reitz, D. B.; Isakson, P. C. (18) (a) Fenesan, I.; Popescu, R.; Scozzafava, A.; Crudin, V.; Matei-
Cyclooxygenase-2 Inhibitors. Current Pharm. Design 1995, 1, ciuc, E.; Bauer, R.; Ilies, M. A.; Supuran, C. T. Carbonic
211-220. (c) Carter, J. S. Recently Reported Inhibitors of anhydrase Inhibitors; Phosphoryl-SulfonamidessA New Class
Cyclooxygenase-2. Exp. Opin. Ther. Patents 1997, 8, 21-29. of High Affinity Inhibitors of Isozymes I and II. J. Enzymol.
(5) Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.-C.; Charleson, S.; Inhibition. 2000, 15, 297-310. (b) Zhu, S.; Xu, G.; Qin, C.; Xu,
Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Y.; Chu, Q. Synthesis of Diethyl N(Perfluoroalkanesulfonyl)-
Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; phosphoramidates and N-(Perfluoroalkanesulfonyl)phosphor-
Kennedy, B.; Leblanc, Y.; Léger, S.; Mancini, J.; O’Neill, G. P.; amidic acids. Phosphorous, Sulfur Silicon Relat. Elem. 1998, 140,
Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, 53-61. (c) Haubold, W.; Becke-Goehring M. Phosphorous
Y.; Tagari, P.; Thérien, M.; Vickers, P.; Wong, E.; Xu, L.-J.; Nitrogen Compounds XXIII. Hydrolysis of Compounds Which
Young, R. N.; Zamboni, R. The Discovery of Rofecoxib, [MK 966, Contain Trichlorophosphazo Group. Z. Anorg. Allg. Chem. 1967,
Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)furanone], an 352, 113-121. (d) Ishimaru, T.; Kodama, Y. German Patent
Orally Active Cyclooxygenase-2 Inhibitor. Bioorg. Med. Chem. Document DE 2344130, 1974.
Lett. 1999, 9, 1773-1778. (19) Murdock, K. C.; Lee, V. L.; Citarella, R. V.; Durr, F. E.; Nicolau,
(6) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; G.; Kohlbrenner, M. N-Phosphoryl Derivatives of Bisantrene.
Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. Antitumor Prodrugs with Enhanced Solubility and Reduced
W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Potential for Toxicity. J. Med. Chem. 1993, 36, 2098-2101.
Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; (20) Hargreaves, K.; Dubner, R.; Brown, F.; Flores, C.; Joris, J. A
Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; new and sensitive method for measuring thermal nociception
Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation in cutaneous hyperalgesia. Pain 1988, 32, 77-88.
of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: (21) Ionization constants were measured by potentiometric titration
Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H- in 0.15 M KCl at 25 °C using a PCA200 instrument (Sirius
pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J. Med. Analytical Instruments).
Chem. 1997, 40, 1347-1365. (22) Equilibrium solubilities were obtained by adding solid com-
(7) Talley, J. J.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Koboldt, pounds directly to an aqueous medium, followed by stirring at
C. M.; Masferrer, J. L.; Perkins, W. E.; Rogers, R. S.; Shaffer, room temperature for 16 h. Suspensions were then filtered and
A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3- the remaining concentration in the solution was measured by
phenylisoxazol-4-yl]-benzenesulfonamide, Valdecoxib: A Potent HPLC.
and Selective Inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-
777. JM040844J